CAS 1195765-45-7

Dabrafenib

Description:

Dabrafenib is a small-molecule inhibitor primarily used in the treatment of certain types of cancer, particularly melanoma with BRAF V600E mutations. It functions by selectively inhibiting the BRAF protein, which is part of the MAPK/ERK signaling pathway, thereby disrupting the proliferation of cancer cells. The substance is characterized by its molecular formula, which includes carbon, hydrogen, nitrogen, and oxygen atoms, and it has a specific molecular weight. Dabrafenib is typically administered orally and is known for its relatively high bioavailability. Its pharmacokinetics indicate a moderate half-life, allowing for once or twice daily dosing. Common side effects may include fever, fatigue, and skin-related reactions, reflecting its impact on both cancerous and normal cells. Additionally, it is often used in combination with other therapies, such as trametinib, to enhance its efficacy. As with many targeted therapies, monitoring for resistance mutations is crucial for maintaining treatment effectiveness.

Formula: C₂₃H₂₀F₃N₅O₂S₂

InChI: InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)

InChI key: InChIKey=BFSMGDJOXZAERB-UHFFFAOYSA-N

SMILES: FC1=C(C2=C(SC(C(C)(C)C)=N2)C3=NC(N)=NC=C3)C=CC=C1NS(=O)(=O)C4=C(F)C=CC=C4F

Synonyms:

• Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-
• Dabarefenib
• Dabrafenib
• Debrafenib free base
• Gsk 2118436
• Gsk 436
• N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
• N-[3-[5-(2-Aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
• Tafinlar
• Tafmlar

Dabrafenib

CAS: 1195765-45-7

Dabrafenib

Purity: ≥98%

Molecular weight: 519.56g/mol

Ref: 54-BUP16984

Dabrafenib

CAS: 1195765-45-7

Formula: C₂₃H₂₀F₃N₅O₂S₂

Color and Shape: Off-White Solid

Molecular weight: 519.57

Ref: 4Z-D-108001

Dabrafenib

CAS: 1195765-45-7

Formula: C₂₃H₂₀F₃N₅O₂S₂

Molecular weight: 519.56

Ref: 7W-GP7467

Dabrafenib

CAS: 1195765-45-7

Dabrafenib (GSK2118436A) is a Raf inhibitor that inhibits C-Raf and B-RafV600E (IC50=5/0.6 nM) and is ATP-competitive.

Formula: C₂₃H₂₀F₃N₅O₂S₂

Purity: 99.62% - >99.99%

Color and Shape: Solid

Molecular weight: 519.56

Ref: TM-T1903

Dabrafenib

CAS: 1195765-45-7

Applications Dabrafenib is an inhibitor of mutated BRAF kinase and has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
References Hauschild, A., et al.: Lancet, 380, 358 (2012); Falchook, G.S., et al.: Lancet, 379, 1893 (2012); Ascierto, P.A., et al.: J. Clin. Oncol., 31, 3205 (2013);

Formula: C₂₃H₂₀F₃N₅O₂S₂

Color and Shape: Neat

Molecular weight: 519.56

Ref: TR-D101000

Dabrafenib

CAS: 1195765-45-7

Inhibitor of mutant B-rafV600E protein that results in decreased proliferation of cancer cells with this mutation. Treatment of metastatic melanoma in patients harboring the V600E mutation, had improved disease outcome. This antitumor activity is enhanced when combined with MEK inhibitor trametinib.

Formula: C₂₃H₂₀F₃N₅O₂S₂

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 519.56 g/mol

Ref: 3D-FA65034